147 related articles for article (PubMed ID: 19663727)
1. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract][Full Text] [Related]
2. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
Niculescu-Duvaz D; Gaulon C; Dijkstra HP; Niculescu-Duvaz I; Zambon A; Ménard D; Suijkerbuijk BM; Nourry A; Davies L; Manne H; Friedlos F; Ogilvie L; Hedley D; Whittaker S; Kirk R; Gill A; Taylor RD; Raynaud FI; Moreno-Farre J; Marais R; Springer CJ
J Med Chem; 2009 Apr; 52(8):2255-64. PubMed ID: 19323560
[TBL] [Abstract][Full Text] [Related]
3. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Zambon A; Ménard D; Suijkerbuijk BM; Niculescu-Duvaz I; Whittaker S; Niculescu-Duvaz D; Nourry A; Davies L; Manne HA; Lopes F; Preece N; Hedley D; Ogilvie LM; Kirk R; Marais R; Springer CJ
J Med Chem; 2010 Aug; 53(15):5639-55. PubMed ID: 20597484
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
5. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
7. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
[TBL] [Abstract][Full Text] [Related]
8. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
Ménard D; Niculescu-Duvaz I; Dijkstra HP; Niculescu-Duvaz D; Suijkerbuijk BM; Zambon A; Nourry A; Roman E; Davies L; Manne HA; Friedlos F; Kirk R; Whittaker S; Gill A; Taylor RD; Marais R; Springer CJ
J Med Chem; 2009 Jul; 52(13):3881-91. PubMed ID: 19473026
[TBL] [Abstract][Full Text] [Related]
9. BRAF as therapeutic target in melanoma.
Wellbrock C; Hurlstone A
Biochem Pharmacol; 2010 Sep; 80(5):561-7. PubMed ID: 20350535
[TBL] [Abstract][Full Text] [Related]
10. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
11. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
[TBL] [Abstract][Full Text] [Related]
12. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
13. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
14. BRAF signaling and targeted therapies in melanoma.
Dhomen N; Marais R
Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Metzner T; Bedeir A; Held G; Peter-Vörösmarty B; Ghassemi S; Heinzle C; Spiegl-Kreinecker S; Marian B; Holzmann K; Grasl-Kraupp B; Pirker C; Micksche M; Berger W; Heffeter P; Grusch M
J Invest Dermatol; 2011 Oct; 131(10):2087-95. PubMed ID: 21753785
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Xie P; Streu C; Qin J; Bregman H; Pagano N; Meggers E; Marmorstein R
Biochemistry; 2009 Jun; 48(23):5187-98. PubMed ID: 19371126
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
18. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
19. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
James J; Ruggeri B; Armstrong RC; Rowbottom MW; Jones-Bolin S; Gunawardane RN; Dobrzanski P; Gardner MF; Zhao H; Cramer MD; Hunter K; Nepomuceno RR; Cheng M; Gitnick D; Yazdanian M; Insko DE; Ator MA; Apuy JL; Faraoni R; Dorsey BD; Williams M; Bhagwat SS; Holladay MW
Mol Cancer Ther; 2012 Apr; 11(4):930-41. PubMed ID: 22319199
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
